EVT only (n=158) | IV tPA+EVT (n=96) | P value | |
Age, mean±SD | 71.2±12.63 | 69.8±13.29 | 0.424 |
Ethnicity | |||
African, n (%) | 1 (0.6) | 0 (0) | |
Hispanic, n (%) | 118 (74.7) | 72 (75) | |
White, n (%) | 38 (24.1) | 22 (22.9) | |
Other, n (%) | 0 (0) | 0 (0) | 0.636 |
Sex | |||
Men, n (%) | 80 (50.6) | 55 (57.3) | |
Women, n (%) | 78 (49.4) | 41 (42.7%) | 0.303 |
NIHSS at admission, median (range) | 16 (0–36) | 19 (0–36) | 0.006 |
Time to presentation, hours, mean±SD | 4.23±3.32 | 3.02±2.58 | 0.08 |
Morbidities | |||
Hypertension, n (%) | 137 (86.7) | 82 (85.4) | 0.772 |
Atrial fibrillation, n (%) | 50 (31.6) | 26 (27.1) | 0.441 |
Coronary artery disease, n (%) | 52 (32.9) | 27 (28.1) | 0.424 |
Hyperlipidemia, n (%) | 102 (64.6) | 53 (55.2) | 0.139 |
Diabetes mellitus, n (%) | 77 (48.7) | 37 (38.5) | 0.113 |
History of stroke/TIA, n (%) | 37 (23.4) | 17 (17.7) | 0.281 |
Currently smoking, n (%) | 15 (9.5) | 13 (13.5) | 0.318 |
Prior aspirin use, n (%) | 57 (36.1) | 43 (44.8) | 0.168 |
Warfarin use, n (%) | 13 (8.2) | 4 (4.2) | 0.209 |
EVT, endovascular treatment; IV tPA, intravenous tissue plasminogen activator; TIA, transient ischemic attack.